{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:21:23Z","timestamp":1787829683321,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K08600"],"award-info":[{"award-number":["JP23K08600"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06758"],"award-info":[{"award-number":["23K06758"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01444-7","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:53:03Z","timestamp":1787827983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment of a patient-derived malignant peripheral nerve sheath tumor organoid model reveals SHH pathway activation and therapeutic vulnerability"],"prefix":"10.1007","volume":"39","author":[{"given":"Haruki","family":"Matsuoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Sasagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nagamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Kukita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Sabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironari","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kakunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinari","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Imura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-0595","authenticated-orcid":false,"given":"Toru","family":"Wakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"1444_CR1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.soc.2016.05.009","volume":"25","author":"AW James","year":"2016","unstructured":"James AW, Shurell E, Singh A, Dry SM, Eilber FC. Malignant peripheral nerve sheath tumor. Surg Oncol Clin N Am. 2016;25:789\u2013802. https:\/\/doi.org\/10.1016\/j.soc.2016.05.009.","journal-title":"Surg Oncol Clin N Am"},{"key":"1444_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","volume":"19","author":"M Farid","year":"2014","unstructured":"Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19:193\u2013201. https:\/\/doi.org\/10.1634\/theoncologist.2013-0328.","journal-title":"Oncologist"},{"key":"1444_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.anndiagpath.2013.10.007","volume":"18","author":"K Thway","year":"2014","unstructured":"Thway K, Fisher C. Malignant peripheral nerve sheath tumor: pathology and genetics. Ann Diagn Pathol. 2014;18:109\u201316. https:\/\/doi.org\/10.1016\/j.anndiagpath.2013.10.007.","journal-title":"Ann Diagn Pathol"},{"key":"1444_CR4","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1245\/s10434-011-1978-7","volume":"19","author":"C-CH Stucky","year":"2012","unstructured":"Stucky C-CH, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19:878\u201385. https:\/\/doi.org\/10.1245\/s10434-011-1978-7.","journal-title":"Ann Surg Oncol"},{"key":"1444_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-4-55","volume":"4","author":"M Kar","year":"2006","unstructured":"Kar M, Deo SVS, Shukla NK, Malik A, DattaGupta S, Mohanti BK, et al. Malignant peripheral nerve sheath tumors (MPNST) \u2013 clinicopathological study and treatment outcome of twenty-four cases. World J Surg Oncol. 2006;4:55. https:\/\/doi.org\/10.1186\/1477-7819-4-55.","journal-title":"World J Surg Oncol"},{"key":"1444_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/jso.20971","volume":"97","author":"SR Grobmyer","year":"2008","unstructured":"Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340\u20139. https:\/\/doi.org\/10.1002\/jso.20971.","journal-title":"J Surg Oncol"},{"key":"1444_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8335290","volume":"2021","author":"Y Imura","year":"2021","unstructured":"Imura Y, Outani H, Takenaka S, Yasuda N, Nakai S, Nakai T, et al. Clinical outcomes and prognostic factors for patients with malignant peripheral nerve sheath tumour. Sarcoma. 2021;2021:1\u20139. https:\/\/doi.org\/10.1155\/2021\/8335290.","journal-title":"Sarcoma"},{"key":"1444_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DGR Evans","year":"2002","unstructured":"Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311\u20134. https:\/\/doi.org\/10.1136\/jmg.39.5.311.","journal-title":"J Med Genet"},{"key":"1444_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1212\/01.wnl.0000173031.99330.13","volume":"65","author":"T Tucker","year":"2005","unstructured":"Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005;65:205\u201311. https:\/\/doi.org\/10.1212\/01.wnl.0000173031.99330.13.","journal-title":"Neurology"},{"key":"1444_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/1096-8628(20000828)93:5<388::AID-AJMG8>3.0.CO;2-#","volume":"93","author":"AA King","year":"2000","unstructured":"King AA, Debaun MR, Riccardi VM, Gutmann DH. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet. 2000;93:388\u201392.","journal-title":"Am J Med Genet"},{"key":"1444_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/humu.20601","volume":"29","author":"M Upadhyaya","year":"2008","unstructured":"Upadhyaya M, Kluwe L, Spurlock G, Monem B, Majounie E, Mantripragada K, et al. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat. 2008;29:74\u201382. https:\/\/doi.org\/10.1002\/humu.20601.","journal-title":"Hum Mutat"},{"key":"1444_CR12","doi-asserted-by":"publisher","first-page":"i50","DOI":"10.1093\/noajnl\/vdz049","volume":"2","author":"A Pemov","year":"2020","unstructured":"Pemov A, Li H, Presley W, Wallace MR, Miller DT. Genetics of human malignant peripheral nerve sheath tumors. Neuro-Oncol Adv. 2020;2:i50-61. https:\/\/doi.org\/10.1093\/noajnl\/vdz049.","journal-title":"Neuro-Oncol Adv"},{"key":"1444_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/gcc.22446","volume":"56","author":"P Sohier","year":"2017","unstructured":"Sohier P, Luscan A, Lloyd A, Ashelford K, Laurendeau I, Briand\u2010Suleau A, et al. Confirmation of mutation landscape of NF1\u2010associated malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer. 2017;56:421\u20136. https:\/\/doi.org\/10.1002\/gcc.22446.","journal-title":"Genes Chromosomes Cancer"},{"key":"1444_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","volume":"13","author":"I Cortes-Ciriano","year":"2023","unstructured":"Cortes-Ciriano I, Steele CD, Piculell K, Al-Ibraheemi A, Eulo V, Bui MM, et al. Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. Cancer Discov. 2023;13:654\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0786.","journal-title":"Cancer Discov"},{"key":"1444_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/modpathol.2015.134","volume":"29","author":"I-M Schaefer","year":"2016","unstructured":"Schaefer I-M, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29:4\u201313. https:\/\/doi.org\/10.1038\/modpathol.2015.134.","journal-title":"Mod Pathol"},{"key":"1444_CR16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","volume":"46","author":"W Lee","year":"2014","unstructured":"Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1227\u201332. https:\/\/doi.org\/10.1038\/ng.3095.","journal-title":"Nat Genet"},{"key":"1444_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/modpathol.2016.45","volume":"29","author":"AHG Cleven","year":"2016","unstructured":"Cleven AHG, Sannaa GAA, Briaire-de Bruijn I, Ingram DR, Van De Rijn M, Rubin BP, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29:582\u201390. https:\/\/doi.org\/10.1038\/modpathol.2016.45.","journal-title":"Mod Pathol"},{"key":"1444_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106096","volume":"26","author":"M Magall\u00f3n-Lorenz","year":"2023","unstructured":"Magall\u00f3n-Lorenz M, Terribas E, Ortega-Bertran S, Creus-Bachiller E, Fern\u00e1ndez M, Requena G, et al. Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. iScience. 2023;26:106096. https:\/\/doi.org\/10.1016\/j.isci.2023.106096.","journal-title":"iScience"},{"key":"1444_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s13577-021-00643-8","volume":"35","author":"Y Sin","year":"2022","unstructured":"Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Akiyama T, et al. Establishment and characterization of NCC-MPNST6-C1: a novel patient-derived cell line of malignant peripheral nerve sheath tumors. Hum Cell. 2022;35:400\u20137. https:\/\/doi.org\/10.1007\/s13577-021-00643-8.","journal-title":"Hum Cell"},{"key":"1444_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03845-4","volume":"25","author":"S Ortega-Bertran","year":"2025","unstructured":"Ortega-Bertran S, Creus-Bachiller E, Magall\u00f3n-Lorenz M, Carri\u00f3 M, Gel B, Villanueva A, et al. New models for MPNST: establishment and comprehensive characterization of two tumor cell lines. Cancer Cell Int. 2025;25:268. https:\/\/doi.org\/10.1186\/s12935-025-03845-4.","journal-title":"Cancer Cell Int"},{"key":"1444_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.15252\/emmm.201404430","volume":"7","author":"J Castellsagu\u00e9","year":"2015","unstructured":"Castellsagu\u00e9 J, Gel B, Fern\u00e1ndez\u2010Rodr\u00edguez J, Llatj\u00f3s R, Blanco I, Benavente Y, et al. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med. 2015;7:608\u201327. https:\/\/doi.org\/10.15252\/emmm.201404430.","journal-title":"EMBO Mol Med"},{"key":"1444_CR22","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2019","unstructured":"Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364:952\u20135. https:\/\/doi.org\/10.1126\/science.aaw6985.","journal-title":"Science"},{"key":"1444_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0662-9","volume":"11","author":"H Xu","year":"2018","unstructured":"Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol. 2018;11:116. https:\/\/doi.org\/10.1186\/s13045-018-0662-9.","journal-title":"J Hematol Oncol"},{"key":"1444_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.stem.2023.05.012","volume":"30","author":"HHN Yan","year":"2023","unstructured":"Yan HHN, Chan AS, Lai FP-L, Leung SY. Organoid cultures for cancer modeling. Cell Stem Cell. 2023;30:917\u201337. https:\/\/doi.org\/10.1016\/j.stem.2023.05.012.","journal-title":"Cell Stem Cell"},{"key":"1444_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318. https:\/\/doi.org\/10.1038\/s41568-018-0007-6.","journal-title":"Nat Rev Cancer"},{"key":"1444_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-32030-w","volume":"16","author":"T Wakamatsu","year":"2025","unstructured":"Wakamatsu T, Yamada Y, Yoshida K, Matsuoka Y, Sasagawa S, Nagamine N, et al. Development of synovial sarcoma organoids exhibiting ferroptosis resistance despite low malic enzyme 1 expression. Sci Rep. 2025;16:2369. https:\/\/doi.org\/10.1038\/s41598-025-32030-w.","journal-title":"Sci Rep"},{"key":"1444_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-025-01308-6","volume":"38","author":"Y Yoshimura","year":"2025","unstructured":"Yoshimura Y, Yoshida K, Matsuoka Y, Sasagawa S, Nagamine N, Kukita Y, et al. Establishment of human histiocytic sarcoma organoids dependent on the SHH\/YAP pathway. Hum Cell. 2025;38:175. https:\/\/doi.org\/10.1007\/s13577-025-01308-6.","journal-title":"Hum Cell"},{"key":"1444_CR28","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1038\/s41598-025-33061-z","volume":"16","author":"H Takami","year":"2025","unstructured":"Takami H, Yoshida K, Matsuoka Y, Sasagawa S, Nagamine N, Kukita Y, et al. Chondrosarcoma organoids reveal SHH pathway activation driven by PTCH1 and BCOR alterations. Sci Rep. 2025;16:3239. https:\/\/doi.org\/10.1038\/s41598-025-33061-z.","journal-title":"Sci Rep"},{"key":"1444_CR29","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.stem.2024.08.010","volume":"31","author":"A Al Shihabi","year":"2024","unstructured":"Al Shihabi A, Tebon PJ, Nguyen HTL, Chantharasamee J, Sartini S, Davarifar A, et al. The landscape of drug sensitivity and resistance in sarcoma. Cell Stem Cell. 2024;31:1524-1542.e4. https:\/\/doi.org\/10.1016\/j.stem.2024.08.010.","journal-title":"Cell Stem Cell"},{"key":"1444_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.113","volume":"3","author":"S Sasagawa","year":"2024","unstructured":"Sasagawa S, Kumai J, Wakamatsu T, Yui Y. Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma. Cancer Innov. 2024;3:e113. https:\/\/doi.org\/10.1002\/cai2.113.","journal-title":"Cancer Innov"},{"key":"1444_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2486-6","volume":"19","author":"SX Ge","year":"2018","unstructured":"Ge SX, Son EW, Yao R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics. 2018;19:534. https:\/\/doi.org\/10.1186\/s12859-018-2486-6.","journal-title":"BMC Bioinformatics"},{"key":"1444_CR32","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/bioinformatics\/btz854","volume":"36","author":"C Prieto","year":"2020","unstructured":"Prieto C, Barrios D. RaNA-Seq: interactive RNA-Seq analysis from FASTQ files to functional analysis. Bioinformatics. 2020;36:1955\u20136. https:\/\/doi.org\/10.1093\/bioinformatics\/btz854.","journal-title":"Bioinformatics"},{"key":"1444_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","volume":"19","author":"M Endo","year":"2013","unstructured":"Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, et al. Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013;19:450\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1067.","journal-title":"Clin Cancer Res"},{"key":"1444_CR34","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1038\/onc.2013.506","volume":"33","author":"ME Brundage","year":"2014","unstructured":"Brundage ME, Tandon P, Eaves DW, Williams JP, Miller SJ, Hennigan RH, et al. MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene. 2014;33:5626\u201336. https:\/\/doi.org\/10.1038\/onc.2013.506.","journal-title":"Oncogene"},{"key":"1444_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38432-6","volume":"14","author":"S Suppiah","year":"2023","unstructured":"Suppiah S, Mansouri S, Mamatjan Y, Liu JC, Bhunia MM, Patil V, et al. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. Nat Commun. 2023;14:2696. https:\/\/doi.org\/10.1038\/s41467-023-38432-6.","journal-title":"Nat Commun"},{"key":"1444_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00401-012-0954-z","volume":"123","author":"FJ Rodriguez","year":"2012","unstructured":"Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123:295\u2013319. https:\/\/doi.org\/10.1007\/s00401-012-0954-z.","journal-title":"Acta Neuropathol"},{"key":"1444_CR37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/PAS.0000000000000655","volume":"40","author":"S Le Guellec","year":"2016","unstructured":"Le Guellec S, Decouvelaere A-V, Filleron T, Valo I, Charon-Barra C, Robin Y-M, et al. Malignant peripheral nerve sheath tumor is a challenging diagnosis: a systematic pathology review, immunohistochemistry, and molecular analysis in 160 patients from the French Sarcoma Group Database. Am J Surg Pathol. 2016;40:896\u2013908. https:\/\/doi.org\/10.1097\/PAS.0000000000000655.","journal-title":"Am J Surg Pathol"},{"key":"1444_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7709","volume":"6","author":"M Cohen","year":"2015","unstructured":"Cohen M, Kicheva A, Ribeiro A, Blassberg R, Page KM, Barnes CP, et al. Ptch1 and Gli regulate Shh signalling dynamics via multiple mechanisms. Nat Commun. 2015;6:6709. https:\/\/doi.org\/10.1038\/ncomms7709.","journal-title":"Nat Commun"},{"key":"1444_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bbrc.2011.04.047","volume":"409","author":"T Zhang","year":"2011","unstructured":"Zhang T, Chen M, L\u00fc Y, Xing Q, Chen W. A novel mutation of the PTCH1 gene activates the Shh\/Gli signaling pathway in a Chinese family with nevoid basal cell carcinoma syndrome. Biochem Biophys Res Commun. 2011;409:166\u201370. https:\/\/doi.org\/10.1016\/j.bbrc.2011.04.047.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01444-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01444-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01444-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:53:04Z","timestamp":1787827984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01444-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1444"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01444-7","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that this study was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of clinical materials for this study was approved by the Ethics Committee of Osaka International Cancer Institute (approval number: 1710059174\u201312), and all procedures were conducted in accordance with institutional and national ethical guidelines. Written informed consent was obtained from the patients.","order":2,"name":"Ethics","label":"Ethical approval and informed consent of participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"131"}}